cemiplimab (Libtayo®) accepted for use within NHSScotland on an interim basis subject to ongoing evaluation and future reassessment

The SMC has accepted cemiplimab as monotherapy for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or curative radiation.

SPS commentary:

NICE had also previously issued guidance recommending cemiplimab for use within the Cancer Drugs Fund for this indication.


Scottish Medicines Consortium

Resource links:

NICE TA592 Aug 2019